Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma

Annals of Oncology

Volumn 18, Issue 7, 2007, Pages 1196-1202

  Weder, W ^a   Stahel, Rolf A ^a   Bernhard, J ^b,f   Bodis, S ^c   Vogt, P ^a   Ballabeni, P ^b   Lardinois, D ^d   Betticher, D ^e   Schmid, R ^f   Stupp, R ^f   Ris, H B ^c   Jermann, M ^a   Mingrone, W ^g   Roth, A D ^h   Spiliopoulos, A ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^c CANTONAL HOSPITAL AARAU   (Switzerland)

^d Hopital Cantonal de Fribourg   (Switzerland)

^e UNIVERSITY OF BERN   (Switzerland)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^g Département de Chirurgie Oncochirurgie   (Switzerland)

^h GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Extrapleural pneumonectomy; Malignant pleural mesothelioma; Neo adjuvant chemotherapy; Quality of life

Indexed keywords

CISPLATIN; GEMCITABINE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRESS SYNDROME; DYSPNEA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOPENIA; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA AND VOMITING; PLEURA MESOTHELIOMA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; QUALITY OF LIFE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 34547830897     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm093     Document Type: Article

References (33)

1. Pelucchi C, Malvezzi M, La Vecchia C et al. The Mesothelioma epidemic in Western Europe: An update. Br J Cancer 2004; 90 (5): 1022-1024.
2. Hodgson JT, McElvenny DM, Darnton AJ et al. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 2005; 92 (3): 587-593.
3. Peto J, Decaril A, La Vecchia C et al. The European mesothelioma epidemic. Br J Cancer 1999; 79: 666-672.
4. Andreopoulou E, Ross PJ, O'Brien ME et al. The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma. Ann Oncol 2004; 15 (9): 1406-1412.
5. O'Brien ME, Watkins D, Ryan C et al. A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: The MED trial. Ann Oncol 2006; 17 (2): 270-275.
6. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin vs cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-2644.
7. van Meerbeeck JP, Gaafar R. Manegold C et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005; 23 (28): 6881-6889.
8. Treasure T, Waller D, Swift S, Peto J. Radical surgery for mesothelioma. BMJ 2004; 328 (7434): 237-238.
9. Sugarbaker DJ, Flores RM, Jaklitsch MT et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients. J Thorac Cardiovasc Surg 1999; 117 (1): 54-63; discussion 63-65.
10. Butchart EG, Ashcroft T, Barnsley WC, Holden MP. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patents. Thorax 1976; 31 (1): 15-24.
11. Sugarbaker DJ, Jaklitsch MT, Bueno R et al. Preventon, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg 2004; 128 (1): 138-146.
12. Maggi G, Casadio C, Cianci R et al. Trimodality management of malignant pleural mesothelioma. Eur J Cardiothorac Surg 2001; 19 (3): 346-350.
13. Stewart DJ, Martin-Ucar AE, Edwards JG et al. Extra-pleural pneumonectomy for malignant pleural mesothelioma: The risks of induction chemotherapy, right-sided procedures and prolonged operations. Eur J Cardiothorac Surg 2005; 27 (3): 373-378.
14. Byrne MJ, Davidson JA, Musk AW et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: A phase II study. J Clin Oncol 1999; 17 (1): 25-30.
15. Weder W, Kestenholz P, Taverna C et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 2004: 22 (17): 3451-3457.
16. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer 1996; 14: 1-12.
17. de Haes JC, van Knippenberg FC, Neijt JP. Measuring psychological and physical distress in cancer patients: Structure and application of the Rotterdam Symptom Checklist. Br J Cancer 1990; 62 (6): 1034-1038.
18. Sloan JA, Dueck A. Issues for statisticians in conducting analyses and translating results for quality of life end points in clinical trials. J Biopharm Stat 2004; 14 (1): 73-96.
19. Curran D, Sahmoud T, Therasse P et al. Prognostic factors in patients with pleural mesothelioma: The European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998; 16 (1): 145-152.
20. Swiss Association of Cancer Registries. Cancer in Switzerland Vol1. Statistics of Incidence 1995-2003; http://www.asrt.ch/asrt/nwestat/ i2003ch.pdf.
21. Nowak AK, Byrne MJ, Williamson R et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 2002; 87 (5): 491-496.
22. van Haarst JM, Baas P, Manegold C et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 2002; 86 (3): 842-345.
23. Roberts JR, Eustis C, Devore R et al. Induction chemotherapy increases perioperative complications in patients undergoing resection for non-small cell lung cancer. Ann Thorac Surg 2001; 72 (3): 885-888.
24. Boutin C, Rey F, Viallat JR. Prevention of malignant seeding after invasive diagnostic procedures in patents with pleural mesothelioma. A randomized trial of local radiotherapy. Chest 1995; 108 (3): 754-758.
25. de Graaf-Strukowska L, van der Zee J, van Putten W, Senan S. Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura - a single-institution experience with 189 patents. Int J Radiat Oncol Biol Phys 1999; 43 (3): 511-516.
26. Bydder S, Phillips M, Joseph DJ et al. A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. Br J Cancer 2004; 91 (1): 9-10.
27. Baldini EH, Recht A, Strauss GM et al. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 1997; 63 (2): 334-338.
28. Rusch VW, Rosenzweig K, Venkatraman E et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001; 122 (4): 788-795.
29. Stevens CW, Forster KM, Smythe WR, Rice D. Radiotherapy for mesothelioma. Hematol Oncol Clin North Am 2005; 19 (6): 1099-1115.
30. Forster KM, Smythe WR, Starkschall G et al. Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesathelioma: Clinical implementation. Int J Radiat Oncol Biol Phys 2003; 55 (3): 606-616.
31. Chapman E, Berenstein EG, Dieguez M, Ortiz Z. Radiotherapy for malignant pleural mesothelioma. Cochrane Database Syst Rev 2006; 3: CD003880.
32. Steele JP, Shamash J, Evans MT et al. Phase II study of vinorelbine in patients with malignant pleural mesothelioma, J Clin Oncol 2000; 18 (23): 3912-3917.
33. Nowak AK, Stockler MR, Byrne MJ. Assessing quality of life during chemotherapy for pleural mesothelioma: Feasibility, validity, and results.of using the European Organization for Research and Treatment of Canber Core Quality of Life Questionnaire and Lung Cancer Module. J Clin Oncol 2004; 22 (15): 3172-3180.